Plasma osteoprotegerin level on admission is associated with no-reflow phenomenon after primary angioplasty and subsequent left ventricular remodeling in patients with acute ST-segment elevation myocardial infarction

Atherosclerosis

Volumn 221, Issue 1, 2012, Pages 254-259

  Erkol, Ayhan ^a   Oduncu, Vecih ^b   Pala, Selçuk ^b   Kizilirmak, Filiz ^c   Kilicgedik, Alev ^d   Yilmaz, Fatih ^e   Güler, Ahmet ^b   Karabay, Can Yücel ^b   Kirma, Cevat ^b  

^a Kocaeli Derince Education and Research Hospital   (Turkey)

^b KOSUYOLU HEART AND RESEARCH HOSPITAL   (Turkey)

^c Department of Cardiology   (Turkey)

^d Kocaeli State Hospital   (Turkey)

^e Kutahya Tavsanli State Hospital   (Turkey)

Author keywords

Myocardial infarction; No reflow; Osteoprotegerin; Primary angioplasty; Remodeling

Indexed keywords

ANGIOPOIETIN 2; OSTEOPROTEGERIN; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANGIOPLASTY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE REPERFUSION; HEART VENTRICLE REMODELING; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NO REFLOW PHENOMENON; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ADULT; AGED; ANGIOPLASTY, BALLOON, CORONARY; ANGIOPOIETIN-2; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; ODDS RATIO; OSTEOPROTEGERIN; PATIENT ADMISSION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; TURKEY; UP-REGULATION; VENTRICULAR REMODELING;

EID: 84857031362     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.12.031     Document Type: Article

References (30)

1. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
2. Jono S., Ikari Y., Shioi A., et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002, 106:1192-1194.
3. Sandberg W.J., Yndestad A., Øie E., et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 2006, 26:857-863.
4. Crisafulli A., Micari A., Altavilla D., et al. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond) 2005, 109:389-395.
5. Ueland T., Jemtland R., Godang K., et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 2004, 44:1970-1976.
6. Omland T., Ueland T., Jansson A.M., et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008, 51:627-633.
7. Secchiero P., Corallini F., Beltrami A.P., et al. An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis 2010, 210:274-277.
8. Mangan S.H., Campenhout A.V., Rush C., Golledege J. Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumour necrosis factor-a associated with induction of angiopoietin-2. Cardiovasc Res 2007, 76:494-505.
9. Erkol A., Pala S., Ki{dotless}rma C., et al. Relation of circulating osteoprotegerin levels on admission to microvascular obstruction after primary percutaneous coronary intervention. Am J Cardiol 2011, 107:857-862.
10. Galiuto L., Garramone B., Scarà A., et al. The extent of microvascular damage during myocardial contrast echocardiography is superior to other known indexes of post-infarct reperfusion in predicting left ventricular remodeling: results of the multicenter AMICI study. J Am Coll Cardiol 2008, 51:552-559.
11. Gibson C.M., Murphy S.A., Rizzo M.J., et al. The relationship between the TIMI frame count and clinical outcomes after thrombolytic administration. Circulation 1999, 99:1945-1950.
12. van't Hof A.W.J., Liem A., Suryapranata H., et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Circulation 1998, 97:2302-2306.
13. Niccoli G., Burzotta F., Galiuto L., Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol 2009, 54:281-292.
14. Yip H.K., Chen M.C., Chang H.W., et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow flow and no-reflow phenomenon. Chest 2002, 122:1322-1332.
15. Niccoli G., Kharbanda R.K., Crea F., Banning A.P. No-reflow: again prevention is better than treatment. Eur Heart J 2010, 31:2449-2455.
16. Bolognese L., Cerisano G., Buonamici P., et al. Influence of infarct-zone viability on left ventricular remodeling after acute myocardial infarction. Circulation 1997, 96:3353-3359.
17. Bolognese L., Neskovic N., Parodi G., et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation 2002, 106:2351-2357.
18. Dickstein K., Cohen-Solal A., Filippatos G., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008, 29:2388-2442.
19. Prasad A., Stone G.W., Holmes D.R., et al. Reperfusion injury, microvascular dysfunction, and cardioprotection: the dark side of reperfusion. Circulation 2009, 120:2105-2112.
20. Yellon D.M., Hausenloy D.J. Myocardial reperfusion injury. N Engl J Med 2007, 357:1121-1135.
21. Bekkers S.C., Yazdani S.K., Virmani R., et al. MVO: underlying pathophysiology and clinical diagnosis. J Am Coll Cardiol 2010, 55:1649-1660.
22. Sun W.Y., Pitson S.M., Bonder C.S. Tumor necrosis factor-induced neutrophil adhesion occurs via sphingosine kinase-1-dependent activation of endothelial {alpha}5{beta}1 integrin. Am J Pathol 2010, 177:436-446.
23. Olesen P., Ledet T., Rasmussen L.M. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia 2005, 48:561-568.
24. Zauli G., Corallini F., Bossi F., et al. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 2007, 110:536-543.
25. Fiedler U., Scharpfenecker M., Koidl S., et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004, 103:4150-4156.
26. Fiedler U., Reiss Y., Scharpfenecker M., et al. Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation. Nat Med 2006, 12:235-239.
27. Parodi G., Antoniucci D. Left ventricular remodeling after primary percutaneous coronary intervention. Am Heart J 2010, 160:S11-S15.
28. Andersen G.Ø., Knudsen E.C., Aukrust P., et al. Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size. Heart 2011, 97:460-465.
29. Ueland T., Yndestad A., Øie E., et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental HF. Circulation 2005, 111:2461-2468.
30. Ndrepepa G., Tiroch K., Fusaro M., et al. 5-Year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol 2010, 55:2383-2389.